File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/s41537-025-00599-w
- Scopus: eid_2-s2.0-105009256735
- WOS: WOS:001501141000001
- Find via

Supplementary
- Citations:
- Appears in Collections:
Article: Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program
| Title | Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program |
|---|---|
| Authors | Wigman, Johanna T WChing, Ann EeChung, YoonhoEichi, Habiballah RahimiLane, ErlendLangholm, CarstenVaidyam, AdityaByun, Andrew Jin SooHaidar, AnastasiaHartmann, JessicaNunez, AngelaDwyer, DominicNasarudin, Adibah AmaniBorders, OwenScott, IsabelleTamayo, ZailynMatneja, PriyaCho, Kang-IkAddington, JeanAlameda, Luis KArango, CelsoBreitborde, Nicholas J KBroome, Matthew RCadenhead, Kristin SCalkins, Monica EChen, Eric Yu HaiChoi, JimmyConus, PhilippeCorcoran, Cheryl MCornblatt, Barbara ADiaz-Caneja, Covadonga MEllman, Lauren MFusar-Poli, PaoloGaspar, Pablo AGerber, CarlaGlenthøj, Louise BirkedalHorton, Leslie EHui, Christy Lai MingKambeitz, JosephKambeitz-Ilankovic, LanaKeshavan, Matcheri SKim, Sung-WanKoutsouleris, NikolaosLangbein, KerstinMamah, DanielMathalon, Daniel HMittal, Vijay ANordentoft, MeretePearlson, Godfrey DPerez, JesusPerkins, Diana OPowers, Albert RRogers, JackSabb, Fred WSchiffman, JasonShah, Jai LSilverstein, Steven MSmesny, StefanYassin, WalidStone, William SStrauss, Gregory PThompson, Judy LUpthegrove, RachelVerma, SwapnaWang, JijunWolf, Daniel HWolff, PhillipRowland, Laura MD’Alfonso, SimonPasternak, OferBouix, SylvainMcGorry, Patrick DKahn, Rene SKane, John MBearden, Carrie EWoods, Scott WShenton, Martha ENelson, BarnabyBaker, Justin TTorous, JohnSuen, Yi NamAccelerating Medicines Partnership® Schizophrenia |
| Issue Date | 3-Jun-2025 |
| Publisher | Nature Publishing Group UK |
| Citation | Schizophrenia, 2025, v. 11, n. 1 How to Cite? |
| Abstract | Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach to explore the nature of CHR and may help to improve personalized risk prediction. Specifically, digital data enable detailed mapping of experiences, moods and behaviors during longer periods of time (e.g., weeks, months) and offer more insight into patterns over time at the individual level across their routine daily life. However, while novel digital health technologies open up many new avenues of research, they also come with specific challenges, including replicability of results and the adherence of participants. This paper outlines the design of the digital component of the Accelerating Medicines Partnership® Schizophrenia Program (AMP SCZ) project, a large international collaborative project that follows individuals at CHR for psychosis over a period of two years. The digital component comprises one-year smartphone-based digital phenotyping and actigraphy. Smartphone-based digital phenotyping includes 30-item short daily self-report surveys and voice diaries as well as passive data capture (geolocation, on/off screen state, and accelerometer). Actigraphy data are collected via an Axivity wristwatch. The aim of this paper is to describe the design and the three goals of the digital measures used in AMP SCZ to: (i) better understand the symptoms, real-life experiences, and behaviors of those at CHR for psychosis, (ii) improve the prediction of transition to psychosis and other health outcomes in this population based on digital phenotyping and, (iii) serve as an example for replicable and ethical research across geographically diverse regions and cultures. Accordingly, we describe the rationale, protocol and implementation of these digital components of the AMP SCZ project. **Link to video interview: https://vimeo.com/1060935583** |
| Persistent Identifier | http://hdl.handle.net/10722/357674 |
| ISSN | 2023 Impact Factor: 3.0 |
| ISI Accession Number ID |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Wigman, Johanna T W | - |
| dc.contributor.author | Ching, Ann Ee | - |
| dc.contributor.author | Chung, Yoonho | - |
| dc.contributor.author | Eichi, Habiballah Rahimi | - |
| dc.contributor.author | Lane, Erlend | - |
| dc.contributor.author | Langholm, Carsten | - |
| dc.contributor.author | Vaidyam, Aditya | - |
| dc.contributor.author | Byun, Andrew Jin Soo | - |
| dc.contributor.author | Haidar, Anastasia | - |
| dc.contributor.author | Hartmann, Jessica | - |
| dc.contributor.author | Nunez, Angela | - |
| dc.contributor.author | Dwyer, Dominic | - |
| dc.contributor.author | Nasarudin, Adibah Amani | - |
| dc.contributor.author | Borders, Owen | - |
| dc.contributor.author | Scott, Isabelle | - |
| dc.contributor.author | Tamayo, Zailyn | - |
| dc.contributor.author | Matneja, Priya | - |
| dc.contributor.author | Cho, Kang-Ik | - |
| dc.contributor.author | Addington, Jean | - |
| dc.contributor.author | Alameda, Luis K | - |
| dc.contributor.author | Arango, Celso | - |
| dc.contributor.author | Breitborde, Nicholas J K | - |
| dc.contributor.author | Broome, Matthew R | - |
| dc.contributor.author | Cadenhead, Kristin S | - |
| dc.contributor.author | Calkins, Monica E | - |
| dc.contributor.author | Chen, Eric Yu Hai | - |
| dc.contributor.author | Choi, Jimmy | - |
| dc.contributor.author | Conus, Philippe | - |
| dc.contributor.author | Corcoran, Cheryl M | - |
| dc.contributor.author | Cornblatt, Barbara A | - |
| dc.contributor.author | Diaz-Caneja, Covadonga M | - |
| dc.contributor.author | Ellman, Lauren M | - |
| dc.contributor.author | Fusar-Poli, Paolo | - |
| dc.contributor.author | Gaspar, Pablo A | - |
| dc.contributor.author | Gerber, Carla | - |
| dc.contributor.author | Glenthøj, Louise Birkedal | - |
| dc.contributor.author | Horton, Leslie E | - |
| dc.contributor.author | Hui, Christy Lai Ming | - |
| dc.contributor.author | Kambeitz, Joseph | - |
| dc.contributor.author | Kambeitz-Ilankovic, Lana | - |
| dc.contributor.author | Keshavan, Matcheri S | - |
| dc.contributor.author | Kim, Sung-Wan | - |
| dc.contributor.author | Koutsouleris, Nikolaos | - |
| dc.contributor.author | Langbein, Kerstin | - |
| dc.contributor.author | Mamah, Daniel | - |
| dc.contributor.author | Mathalon, Daniel H | - |
| dc.contributor.author | Mittal, Vijay A | - |
| dc.contributor.author | Nordentoft, Merete | - |
| dc.contributor.author | Pearlson, Godfrey D | - |
| dc.contributor.author | Perez, Jesus | - |
| dc.contributor.author | Perkins, Diana O | - |
| dc.contributor.author | Powers, Albert R | - |
| dc.contributor.author | Rogers, Jack | - |
| dc.contributor.author | Sabb, Fred W | - |
| dc.contributor.author | Schiffman, Jason | - |
| dc.contributor.author | Shah, Jai L | - |
| dc.contributor.author | Silverstein, Steven M | - |
| dc.contributor.author | Smesny, Stefan | - |
| dc.contributor.author | Yassin, Walid | - |
| dc.contributor.author | Stone, William S | - |
| dc.contributor.author | Strauss, Gregory P | - |
| dc.contributor.author | Thompson, Judy L | - |
| dc.contributor.author | Upthegrove, Rachel | - |
| dc.contributor.author | Verma, Swapna | - |
| dc.contributor.author | Wang, Jijun | - |
| dc.contributor.author | Wolf, Daniel H | - |
| dc.contributor.author | Wolff, Phillip | - |
| dc.contributor.author | Rowland, Laura M | - |
| dc.contributor.author | D’Alfonso, Simon | - |
| dc.contributor.author | Pasternak, Ofer | - |
| dc.contributor.author | Bouix, Sylvain | - |
| dc.contributor.author | McGorry, Patrick D | - |
| dc.contributor.author | Kahn, Rene S | - |
| dc.contributor.author | Kane, John M | - |
| dc.contributor.author | Bearden, Carrie E | - |
| dc.contributor.author | Woods, Scott W | - |
| dc.contributor.author | Shenton, Martha E | - |
| dc.contributor.author | Nelson, Barnaby | - |
| dc.contributor.author | Baker, Justin T | - |
| dc.contributor.author | Torous, John | - |
| dc.contributor.author | Suen, Yi Nam | - |
| dc.contributor.author | Accelerating Medicines Partnership® Schizophrenia | - |
| dc.date.accessioned | 2025-07-22T03:14:13Z | - |
| dc.date.available | 2025-07-22T03:14:13Z | - |
| dc.date.issued | 2025-06-03 | - |
| dc.identifier.citation | Schizophrenia, 2025, v. 11, n. 1 | - |
| dc.identifier.issn | 2754-6993 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/357674 | - |
| dc.description.abstract | <p>Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach to explore the nature of CHR and may help to improve personalized risk prediction. Specifically, digital data enable detailed mapping of experiences, moods and behaviors during longer periods of time (e.g., weeks, months) and offer more insight into patterns over time at the individual level across their routine daily life. However, while novel digital health technologies open up many new avenues of research, they also come with specific challenges, including replicability of results and the adherence of participants. This paper outlines the design of the digital component of the Accelerating Medicines Partnership® Schizophrenia Program (AMP SCZ) project, a large international collaborative project that follows individuals at CHR for psychosis over a period of two years. The digital component comprises one-year smartphone-based digital phenotyping and actigraphy. Smartphone-based digital phenotyping includes 30-item short daily self-report surveys and voice diaries as well as passive data capture (geolocation, on/off screen state, and accelerometer). Actigraphy data are collected via an Axivity wristwatch. The aim of this paper is to describe the design and the three goals of the digital measures used in AMP SCZ to: (i) better understand the symptoms, real-life experiences, and behaviors of those at CHR for psychosis, (ii) improve the prediction of transition to psychosis and other health outcomes in this population based on digital phenotyping and, (iii) serve as an example for replicable and ethical research across geographically diverse regions and cultures. Accordingly, we describe the rationale, protocol and implementation of these digital components of the AMP SCZ project. **Link to video interview: <a href="https://vimeo.com/1060935583">https://vimeo.com/1060935583</a>**<br></p> | - |
| dc.language | eng | - |
| dc.publisher | Nature Publishing Group UK | - |
| dc.relation.ispartof | Schizophrenia | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.title | Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.1038/s41537-025-00599-w | - |
| dc.identifier.scopus | eid_2-s2.0-105009256735 | - |
| dc.identifier.volume | 11 | - |
| dc.identifier.issue | 1 | - |
| dc.identifier.eissn | 2754-6993 | - |
| dc.identifier.isi | WOS:001501141000001 | - |
